Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

September 3, 2020

Primary Completion Date

August 5, 2021

Study Completion Date

August 23, 2021

Conditions
COVID-19
Interventions
DRUG

Paracetamol

SOC - 2 tablets (1000 mg) to be taken 6-hourly as needed

DRUG

Artesunate-amodiaquine

SOC plus artesunate-amodiaquine (ASAQ) - 2 tablets (200/540 mg artesunate/amodiaquine) daily for 3 days

DRUG

Pyronaridine-artesunate

SOC plus pyronaridine-artesunate (PA) Weight 45 to \<65 kg: 3 tablets (540/180 mg pyronaridine/artesunate) daily for 3 days Weight ≥65 kg: 4 tablets (720/240 mg pyronaridine/artesunate) daily for 3 days

DRUG

Favipiravir plus Nitazoxanide

SOC plus favipiravir plus nitazoxanide (FPV-NTZ) Favipiravir: 1600 mg 12-hourly for 1 day then 600 mg 12-hourly for 6 days Nitazoxanide: 2 tablets (1000 mg) 12-hourly for 7 days

DRUG

Sofosbuvir/daclatasvir

"SOC plus sofosbuvir/daclatasvir (SOF/DCV)~1 tablet (400 mg/60 mg sofosbuvir/daclatasvir) daily for 7 days"

Trial Locations (1)

Unknown

Ezintsha, Wits Reproductive Health & HIV Institute University of the Witwatersrand, Johannesburg

All Listed Sponsors
collaborator

Medicines for Malaria Venture

OTHER

lead

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY

NCT04532931 - Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19 | Biotech Hunter | Biotech Hunter